Ensysce Biosciences ENSC Stock
Ensysce Biosciences Price Chart
Ensysce Biosciences ENSC Financial and Trading Overview
| Ensysce Biosciences stock price | 0.74 USD |
| Previous Close | 1.25 USD |
| Open | 1.29 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 4000 |
| Day's Range | 1.21 - 1.29 USD |
| 52 Week Range | 1.21 - 63.6 USD |
| Volume | 4.31K USD |
| Avg. Volume | 57.96K USD |
| Market Cap | 3.47M USD |
| Beta (5Y Monthly) | 0.52697 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.69 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.72 USD |
ENSC Valuation Measures
| Enterprise Value | -231098 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.28360656 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.1587101 |
| Price/Book (mrq) | 0.78483474 |
| Enterprise Value/Revenue | -0.077 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Ensysce Biosciences Stock Price History
| Beta (5Y Monthly) | 0.52697 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 63.6 USD |
| 52 Week Low | 1.21 USD |
| 50-Day Moving Average | 1.8 USD |
| 200-Day Moving Average | 4.37 USD |
ENSC Share Statistics
| Avg. Volume (3 month) | 57.96K USD |
| Avg. Daily Volume (10-Days) | 22.89K USD |
| Shares Outstanding | 2.86M |
| Float | 2.42M |
| Short Ratio | 0.89 |
| % Held by Insiders | 4.30% |
| % Held by Institutions | 5.96% |
| Shares Short | 26.49K |
| Short % of Float | 0.95% |
| Short % of Shares Outstanding | 0.92% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | June 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -575.33% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -150.44% |
| Return on Equity (ttm) | -1319.74% |
Income Statement
| Revenue (ttm) | 2.99M USD |
| Revenue Per Share (ttm) | 3.15 USD |
| Quarterly Revenue Growth (yoy) | 136.40% |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -19851664 USD |
| Diluted EPS (ttm) | -58.29 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.83M USD |
| Total Cash Per Share (mrq) | 1.34 USD |
| Total Debt (mrq) | 456.66K USD |
| Total Debt/Equity (mrq) | 12.04 USD |
| Current Ratio (mrq) | 2.326 |
| Book Value Per Share (mrq) | 1.543 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16725392 USD |
| Levered Free Cash Flow (ttm) | -12218706 USD |
Profile of Ensysce Biosciences
| Country | United States |
| State | CA |
| City | La Jolla |
| Address | 7946 Ivanhoe Avenue |
| ZIP | 92037 |
| Phone | 858 263 4196 |
| Website | https://www.ensysce.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 7 |
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla, California.
Q&A For Ensysce Biosciences Stock
What is a current ENSC stock price?
Ensysce Biosciences ENSC stock price today per share is 0.74 USD.
How to purchase Ensysce Biosciences stock?
You can buy ENSC shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ensysce Biosciences?
The stock symbol or ticker of Ensysce Biosciences is ENSC.
Which industry does the Ensysce Biosciences company belong to?
The Ensysce Biosciences industry is Biotechnology.
How many shares does Ensysce Biosciences have in circulation?
The max supply of Ensysce Biosciences shares is 7.33M.
What is Ensysce Biosciences Price to Earnings Ratio (PE Ratio)?
Ensysce Biosciences PE Ratio is now.
What was Ensysce Biosciences earnings per share over the trailing 12 months (TTM)?
Ensysce Biosciences EPS is -4.69 USD over the trailing 12 months.
Which sector does the Ensysce Biosciences company belong to?
The Ensysce Biosciences sector is Healthcare.
Ensysce Biosciences ENSC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}